Expiration date: 03/2025

The composition and form of issue:

Eye ointment 1%. 1 g contains:

hydrocortisone acetate 10,0 mg

excipients: white vaseline liquid paraffin lanolin 

in tube 2.5 g in a cardboard bundle 1 tuba.

Ointment ophthalmic 2.5%. 1 g contains:

hydrocortisone acetate 25.0 mg

excipients: white vaseline liquid paraffin lanolin 

in tube 2.5 g in a cardboard bundle 1 tuba.

Description pharmaceutical form:

White to yellowish homogeneous suspension ointment.

Pharmacokinetics:

Possible penetration of hydrocortisone acetate across the cornea in the anterior chamber of the eye due to the lipophilic properties. The penetration of hydrocortisone acetate in the tissue depends on the condition of the cornea, and significantly increases in case of inflammation or damage to eye.

Description pharmacological action:

The drug contains as the active substance hydrocortisone acetate (corticosteroids).

The local application of hydrocortisone acetate suppresses inflammatory and allergic reactions that occur in the outer shell and the anterior segment of the eye.

The effect of hydrocortisone acetate, like other corticosteroids, is based on the suppression of the function of leukocytes and tissue macrophages. Restricts the migration of leukocytes in the area of inflammation. Violates the ability of macrophages to phagocytosis and the formation of IL-1. Contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in inflammation. Decreases capillary permeability caused by histamine release. Inhibits the activity of fibroblasts and collagen formation. Inhibits the activity of phospholipase A2 which leads to suppression of the synthesis of PG and leukotrienes.

Indications:

• allergic conjunctivitis, blepharitis, blepharoconjunctivitis
  
• acute and chronic iritis, iridocyclitis
  
• inflammation after surgery on the eyeball
  
• the suppression of the neovascularization after myocardial keratitis, chemical burns.
  

Contraindications:

• hypersensitivity to any component of the drug
  
• superficial corneal herpes and other viral diseases of the eye
  
• the violation of the integrity of the epithelium and damage to the cornea
  
• tuberculosis, bacterial or fungal eye infection
  
• trachoma
  
• the vaccination period.
  

Application of pregnancy and breast-feeding:

To date clinical trial data regarding the use of the drug Hydrocortisone–POS during pregnancy, lactation and in children do not exist. Perhaps the use of this drug for the treatment of children older than 1 year, pregnant women and nursing mothers on the prescription of the medical doctor, if the expected therapeutic effect exceeds the risk of possible side effects. The duration of the drug in this category of patients is not more than 7-10 days.

Side effects:

If drug treatment Hydrocortisone–POS has developed a side effect not listed in this leaflet, or no confidence in the effectiveness of the drug, you should inform the attending physician.

In very rare cases allergic reactions such as contact dermatitis, dermatoconjunctivitis, eczema of the eyelids.

Prolonged drug use can cause secondary glaucoma and complicated cataracts, so when using the drug for more than 2 weeks, and in patients with a history of glaucoma, it is recommended to regularly control the intraocular pressure.

In the case of side effects, discontinue using the drug and contact your doctor (ophthalmologist).

Drug interactions:

The simultaneous use of Hydrocortisone, PIC and other means that may cause increased intraocular pressure (e.g. atropine and other cholinergic drugs) may contribute to a further increase in intraocular pressure, especially in patients predisposed to it.

Method of application and dose:

Into the conjunctival SAC. In the absence of other recommendations be sure to follow the instructions for use of the drug Hydrocortisone–POS.

Strip of ointment length of 1 cm is laid 2-3 times a day for the lower eyelid.

To do this, open the tube, slightly tilt the head back and lay the strip of ointment length of 1 cm over the lower eyelid. Gently close your eyes.

After use, tightly close the tube.

During application of eye ointments should be avoid contact of the tube with the surface of the skin or conjunctiva.

Simultaneous application of several eye drugs it is recommended to lay ointment Hydrocortisone–POS no earlier than 15 minutes after use of eye drops.

The duration of treatment eye ointment Hydrocortisone–POS usually no more than 2, maximum 3 weeks.

Overdose:

The local application at the recommended dose symptoms of overdose were not observed.

Special instructions:

During treatment with the drug Hydrocortisone–POS it is not recommended to use contact lenses.

Immediately after use of the drug Hydrocortisone–POS may be temporary violation of visual acuity, leading to slower mental and physical reactions. Therefore it is not recommended to apply the drug directly before working with machinery and driving vehicles.